Overview


Carcinoid Tumor Syndrome (CS) is a clinical condition most commonly associated with neuroendocrine tumors (NETs), particularly when these tumors secrete high levels of serotonin and other vasoactive substances. This syndrome often occurs when the tumors metastasize to the liver or other distant sites, leading to secretory products bypassing hepatic metabolism and entering systemic circulation.

The symptoms of Carcinoid Tumor Syndrome can vary but typically include flushing, diarrhea, abdominal cramping, bronchospasm, and in long-standing cases, carcinoid heart disease. 

The management of Carcinoid Tumor Syndrome focuses on alleviating symptoms, controlling tumor progression, and preventing complications such as heart valve damage. A key strategy for symptom control involves the use of somatostatin analogs, such as octreotide and lanreotide, which help inhibit the secretion of serotonin and related peptides. For patients experiencing refractory symptoms or significant discomfort, telotristat ethyl, a serotonin synthesis inhibitor, may be introduced to help reduce diarrhea.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Carcinoid Tumor Syndrome Management Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Carcinoid Tumor Syndrome Management Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • GlaxoSmithKline plc
  • Roche Holding AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Biogen Inc.
  • Vertex Pharmaceuticals Incorporated
  • Blueprint Medicines Corporation
  • Lantheus Holdings, Inc.
  • Progenics Pharmaceuticals, Inc.
  • Advanced Accelerator Applications (a Novartis company)
  • Chiasma, Inc.

(Note: The list of major players will be updated with the latest market scenario and trends.)

By Organ Affected

  • Small Intestine
  • Lungs
  • Rectum
  • Appendix
  • Stomach
  • Liver
  • Others

By Drug

  • Octreotide
  • TelotristatEtiprate
  • Lanreotide

By Therapy Type

  • Chemotherapy
  • Biological Therapy
  • Radiotherapy

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Carcinoid Tumor Syndrome Management Market By Organ Affected, By Drug, By Therapy Type, By Route of Administration, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size in key regions— North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
  • To record and evaluate the competitive landscape, mapping product launches, technological advancements, mergers, and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Carcinoid Tumor Syndrome Management Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Carcinoid Tumor Syndrome Management Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Carcinoid Tumor Syndrome Management Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Carcinoid Tumor Syndrome Management Market, By Organ Affected Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Small Intestine
      2. Lungs
      3. Rectum
      4. Appendix
      5. Stomach
      6. Liver
      7. Others
  • 8.  Carcinoid Tumor Syndrome Management Market, By Drug Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Octreotide
      2. TelotristatEtiprate
      3. Lanreotide
  • 9.  Carcinoid Tumor Syndrome Management Market, By Therapy Type Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Chemotherapy
      2. Biological Therapy
      3. Radiotherapy
  • 10.  Carcinoid Tumor Syndrome Management Market, By Route of Administration Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Oral
      2. Injectable
  • 11.  Carcinoid Tumor Syndrome Management Market, By Distribution Channel Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Retail Pharmacies
      2. Hospital Pharmacies
      3. Online Pharmacies
  • 12.  North America Carcinoid Tumor Syndrome Management Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 13.  Latin America Carcinoid Tumor Syndrome Management Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 14.  Europe Carcinoid Tumor Syndrome Management Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 15.  Asia Pacific Carcinoid Tumor Syndrome Management Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 16.  Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 17.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 18.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)
    •    1. Pfizer Inc.
        1.1. Company Overview
        1.2. Drug Type Portfolio
        1.3. SWOT Analysis
        1.4. Financial Overview
        1.5. Strategic Overview
         2. Eli Lilly and Company
        2.1. Company Overview
        2.2. Drug Type Portfolio
        2.3. SWOT Analysis
        2.4. Financial Overview
        2.5. Strategic Overview
         3. Bristol-Myers Squibb
        3.1. Company Overview
        3.2. Drug Type Portfolio
        3.3. SWOT Analysis
        3.4. Financial Overview
        3.5. Strategic Overview
         4. GlaxoSmithKline plc
        4.1. Company Overview
        4.2. Drug Type Portfolio
        4.3. SWOT Analysis
        4.4. Financial Overview
        4.5. Strategic Overview
         5. Roche Holding AG
        5.1. Company Overview
        5.2. Drug Type Portfolio
        5.3. SWOT Analysis
        5.4. Financial Overview
        5.5. Strategic Overview
         6. Sanofi S.A.
        6.1. Company Overview
        6.2. Drug Type Portfolio
        6.3. SWOT Analysis
        6.4. Financial Overview
        6.5. Strategic Overview
         7. Merck & Co., Inc.
        7.1. Company Overview
        7.2. Drug Type Portfolio
        7.3. SWOT Analysis
        7.4. Financial Overview
        7.5. Strategic Overview
         8. AstraZeneca plc
        8.1. Company Overview
        8.2. Drug Type Portfolio
        8.3. SWOT Analysis
        8.4. Financial Overview
        8.5. Strategic Overview
         9. Bayer AG
        9.1. Company Overview
        9.2. Drug Type Portfolio
        9.3. SWOT Analysis
        9.4. Financial Overview
        9.5. Strategic Overview
        10. Takeda Pharmaceutical Company Limited
        10.1. Company Overview
        10.2. Drug Type Portfolio
        10.3. SWOT Analysis
        10.4. Financial Overview
        10.5. Strategic Overview
        11. AbbVie Inc.
        11.1. Company Overview
        11.2. Drug Type Portfolio
        11.3. SWOT Analysis
        11.4. Financial Overview
        11.5. Strategic Overview
        12. Regeneron Pharmaceuticals, Inc.
        12.1. Company Overview
        12.2. Drug Type Portfolio
        12.3. SWOT Analysis
        12.4. Financial Overview
        12.5. Strategic Overview
        13. Biogen Inc.
        13.1. Company Overview
        13.2. Drug Type Portfolio
        13.3. SWOT Analysis
        13.4. Financial Overview
        13.5. Strategic Overview
        14. Vertex Pharmaceuticals Incorporated
        14.1. Company Overview
        14.2. Drug Type Portfolio
        14.3. SWOT Analysis
        14.4. Financial Overview
        14.5. Strategic Overview
        15. Blueprint Medicines Corporation
        15.1. Company Overview
        15.2. Drug Type Portfolio
        15.3. SWOT Analysis
        15.4. Financial Overview
        15.5. Strategic Overview
        16. Lantheus Holdings, Inc.
        16.1. Company Overview
        16.2. Drug Type Portfolio
        16.3. SWOT Analysis
        16.4. Financial Overview
        16.5. Strategic Overview
        17. Progenics Pharmaceuticals, Inc.
        17.1. Company Overview
        17.2. Drug Type Portfolio
        17.3. SWOT Analysis
        17.4. Financial Overview
        17.5. Strategic Overview
        18. Advanced Accelerator Applications (a Novartis company)
        18.1. Company Overview
        18.2. Drug Type Portfolio
        18.3. SWOT Analysis
        18.4. Financial Overview
        18.5. Strategic Overview
        19. Chiasma, Inc.
        19.1. Company Overview
        19.2. Drug Type Portfolio
        19.3. SWOT Analysis
        19.4. Financial Overview
        19.5. Strategic Overview

  • 19.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.  FutureWise SME Key Takeaway Points for Client
    •      

Partner

Our Clients